Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report.

ABSTRACT:

Background

Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products.

Objective

To better understand the early impact of emicizumab on our patients at the University of Colorado Hemophilia and Thrombosis Center (UCHTC), we evaluated adverse reactions, factor prophylaxis overlap, and bleeding rates after starting emicizumab through a quality improvement project.

Patients/methods

A retrospective chart review and structured phone interview were conducted from June to September 2019 for all patients who had started emicizumab at the UCHTC. Data about emicizumab dosing, reactions, bleeding events, and bleeding treatment were collected in 68 children and adults

SUBMITTER: Warren BB 

PROVIDER: S-EPMC8331949 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature